PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Alirocumab - Lipid modification

PAD Profile : Alirocumab - Lipid modification

Keywords :
Hyperlipidaemia, PCSK9 inhibitor, lipid regulating, mixed dyslipidaemia, Primary hypercholesterolaemia, lipid-lowering, lipid lowering, raised cholesterol, high cholesterol
Brand Names Include :
Praluent

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Restricted to lipidologists only.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
R
NICE
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 December 2021
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The APC recommends both presentations of alirocumab: 150mg fortnightly (see previous recommendation) AND 300mg monthly (new recommendation).

The monthly 300mg presentation maybe more conveniant for patients.  It was not covered in the evidence base underpinning NICE TA393 but the PAS price is the same monthly cost as 150mg fortnightly.  

Prescribing of either product should be in line with NICE TA393 under the conditions agreed in October 2016
 

05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA393 (June 2016) Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Alirocumab will be considered RED on the traffic light system

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More